Welcome to our dedicated page for Enlivex news (Ticker: ENLV), a resource for investors and traders seeking the latest updates and insights on Enlivex stock.
Enlivex Ltd. develops quality longevity therapeutics and operates a prediction markets treasury alongside its clinical programs. The company’s news centers on Allocetra™, a clinical-stage immunotherapy for inflammatory conditions associated with aging, with a primary focus on moderate-to-severe age-related knee osteoarthritis.
Recurring updates also cover the RAIN token and Rain protocol, including digital asset treasury holdings, exchange listings, decentralized prediction-market infrastructure, tokenized exposure to Enlivex ordinary shares, financial results affected by treasury assets, financing activity, and share repurchase authorization.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) has initiated a multi-center Phase II clinical trial for Allocetra in COVID-19 patients, following promising results in a prior Phase Ib trial for sepsis. The trial aims to assess the safety and efficacy of Allocetra in addressing cytokine storms and organ dysfunction associated with severe COVID-19 symptoms. Up to five patients will be recruited per center, with primary endpoints including changes in PaO2/FiO2 ratio and adverse events. The study runs independently of an upcoming Phase IIb trial for sepsis planned for late 2020.